Miljø, patogener og værtsinteraktioner ved melioidose (DeEPH)
Afkodning af triaden: samspillet mellem miljø, patogen og vært ved melioidose (DeEPH)
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.
The hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.
For each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
This study is funded by the Wellcome Trust. The grant reference number is 323077/Z/24/Z
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems:
- Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (MORU);
- Mahosot Hospital, Vientiane, Lao PDR (LOMWRU); and
- Angkor Hospital for Children, Siem Reap, Cambodia (COMRU).
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
Participant Recruitment and Follow-up
Hospital cohort:
Patients with melioidosis will be recruited at all three hospital sites. The study plans to recruit 1,000 patients, who will be followed longitudinally at six time points: Day 0 (admission), Days 3 and 7 (acute phase), and Days 30, 180, and 365 (recovery phase).
Clinical data collected will include demographic characteristics, underlying comorbidities, environmental exposures, lifestyle and behavioural factors, treatment history, patient-reported medication adherence, and follow-up outcomes.
Healthy controls:
Each patient will be matched with a healthy control recruited within two weeks of diagnosis, based on age, sex, and village of residence. Controls will have no current symptoms or prior history of melioidosis. They will provide a single blood sample at enrolment for DNA extraction and antibody profiling and will be followed up by telephone on Days 180 and 365.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Kamolchanok Claire Chewapreecha, PhD
- Telefonnummer: 662 203 6333
- E-mail: claire@tropmedres.ac
Studiesteder
-
-
-
Siem Reap, Cambodja
- Ikke rekrutterer endnu
- Cambodia-Oxford Medical Research Unit (COMRU)
-
Kontakt:
- Paul Turner, MD
- E-mail: Pault@tropmedres.ac
-
-
-
-
-
Vientiane, Laos
- Ikke rekrutterer endnu
- Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
-
Kontakt:
- Elizabeth Ashley, MD
- E-mail: Elizabeth.Ashley@tropmedres.ac
-
-
-
-
-
Ubon Ratchathani, Thailand
- Rekruttering
- Sunpasitthiprosong Hospital
-
Kontakt:
- Kamolchanok C Chewapreecha, PhD
- Telefonnummer: 022036333
- E-mail: claire@tropmedres.ac
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Melioidosis patients:
Patients confirmed to have melioidosis.
Healthy controls:
For each confirmed melioidosis case, a healthy control-defined as having no current fever, no evidence of soft tissue infection, and no prior history of melioidosis-will be recruited from satellite blood bank donors within approximately two weeks of case identification. Controls will be matched by age (±5 years), sex, and village of residence.
Sandbox Village residents:
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation.
Beskrivelse
Inclusion criteria for melioidosis patients:
- Age ≥20 years
- Positive for Burkholderia pseudomallei from any clinical samples
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for healthy controls:
- Age ≥20 years
- Currently healthy as judged by study doctor
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for sandbox residents:
- Age ≥20 years
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Exclusion criteria for melioidosis patients:
- Current tuberculosis (TB) or TB treatment within the past six months
- Documented HIV infection or use of immunosuppressive therapy in the past 12 months
Exclusion criteria for healthy controls:
- History of melioidosis
- Significant acute illness
- Current fever or soft tissue infection
Exclusion criteria for sandbox residents
-N/A
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Melioidosis patients
Patients confirmed to have melioidosis |
|
Healthy controls
Healthy controls will be enrolled for each confirmed melioidosis case. A healthy control is defined as an individual with no current fever, no evidence of soft tissue infection, and no prior history of melioidosis. Controls will be recruited within approximately two weeks of case identification and will be matched to cases by age (±5 years), sex, and village of residence. |
|
Sandbox village cohort
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Udvikling af melioidose efter eksponering, vurderet blandt melioidose-tilfælde
Tidsramme: 365 dage
|
365 dage
|
|
Udvikling af melioidose efter eksponering, vurderet blandt raske kontroller
Tidsramme: 365 dage
|
365 dage
|
|
Udvikling af melioidose efter eksponering, vurderet blandt beboere i Sandbox Village
Tidsramme: 3,5 år
|
3,5 år
|
|
Dødelighed i den akute fase af infektion blandt personer med melioidose (melioidose-tilfælde).
Tidsramme: 365 dage
|
365 dage
|
|
Antallet af genindlæggelser på hospital efter udskrivelse blandt personer med melioidose (melioidose-tilfælde).
Tidsramme: 365 dage
|
365 dage
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændringer i sygdomsudvikling efter eksponering forbundet med interaktioner mellem miljømæssige ændringer.
Tidsramme: 3,5 år
|
3,5 år
|
|
Ændringer i dødeligheden under den akutte fase af infektion efter eksponering forbundet med interaktioner mellem miljøændringer.
Tidsramme: 365 dage
|
365 dage
|
|
Ændringer i genindlæggelse på hospital efter bedring forbundet med samspil mellem miljøtilpasninger.
Tidsramme: 365 dage
|
365 dage
|
|
Ændringer i sygdomsudviklingen efter eksponering forbundet med interaktioner mellem kliniske behandlingsfaktorer.
Tidsramme: 365 dage
|
365 dage
|
|
Ændringer i dødeligheden under infektionens akutte fase efter eksponering forbundet med interaktioner mellem kliniske behandlingsfaktorer.
Tidsramme: 365 dage
|
365 dage
|
|
Ændringer i genindlæggelse på hospital efter bedring forbundet med interaktioner mellem kliniske behandlingsfaktorer.
Tidsramme: 365 dage
|
365 dage
|
|
Ændringer i sygdomsudviklingen efter eksponering forbundet med interaktioner, der involverer genetisk modtagelighed.
Tidsramme: 365 dage
|
365 dage
|
|
Ændringer i dødeligheden under infektionens akutte fase efter eksponering forbundet med interaktioner, der involverer genetisk modtagelighed.
Tidsramme: 365 dage
|
365 dage
|
|
Ændringer i genindlæggelse på hospital efter bedring forbundet med interaktioner, der involverer genetisk modtagelighed.
Tidsramme: 365 dage
|
365 dage
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Kamolchanok Claire Chewapreecha, PhD, Mahidol Oxford Tropical Research Unit
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- MEL25001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The study outputs, including genomic and transcriptomic data and associated metadata, will be valuable for future research. In compliance with the Wellcome Trust's open data policies and to encourage reproducibility, data will be deposited in two repositories:
Human genomic and transcriptomic data: European Genome-Phenome Archive (EGA), under managed access
Bacterial genomic data: European Nucleotide Archive (ENA), open access
Pseudonymised metadata, including participant demographics and microbiological findings, will be shared with qualified researchers in accordance with the General Data Protection Regulation (GDPR). No personally identifiable information will be shared, and participants will not be identifiable from any released data.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .